###begin article-title 0
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 114 122 <span type="species:ncbi:9606">Patients</span>
Differences in the Contribution of the CTLA4 Gene to Susceptibility to Fulminant and Type 1A Diabetes in Japanese Patients
###end article-title 0
###begin p 1
###xml 37 62 37 62 <email xmlns:xlink="http://www.w3.org/1999/xlink">eijikawa@nagasaki-u.ac.jp</email>
Corresponding author: Eiji Kawasaki, eijikawa@nagasaki-u.ac.jp
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE</bold>
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
OBJECTIVE-To examine the contribution of the CTLA4 gene in the susceptibility to fulminant type 1 diabetes and compare it with classic type 1A diabetes.
###end p 3
###begin p 4
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS</bold>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 174 175 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
RESEARCH DESIGN AND METHODS-We genotyped the +49G>A and CT60G>A variants of the CTLA4 gene in fulminant type 1 diabetic patients (n = 55), classic type 1A diabetic patients (n = 91), and healthy control subjects (n = 369). We also assessed serum levels of the soluble form of CTLA4 (sCTLA4).
###end p 4
###begin p 5
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS</bold>
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 248 251 248 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 253 254 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
RESULTS-The +49GG and CT60GG genotypes were associated with type 1A diabetes (P < 0.001). In contrast, the CT60AA genotype, but not the +49G>A variation, was associated with fulminant type 1 diabetes (P < 0.05), especially in patients carrying HLA-DR4 (P < 0.01). Serum levels of sCTLA4 were significantly decreased in patients with fulminant type 1 diabetes (P < 0.05).
###end p 5
###begin p 6
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS</bold>
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 148 153 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
CONCLUSIONS-These results suggest that CTLA4 CT60 affects the genetic susceptibility to fulminant type 1 diabetes. Furthermore, the contribution of CTLA4 to disease susceptibility is distinct between fulminant type 1 diabetes and classic type 1A diabetes.
###end p 6
###begin p 7
Published ahead of print at  on 28 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 472 480 472 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-VNTR</italic>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 517 522 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 705 706 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 983 988 983 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
Fulminant type 1 diabetes is a subtype of type 1 diabetes characterized by extremely rapid onset that can be classified as type 1B diabetes (1). Although frequent flu-like symptoms prior to onset suggest the contribution of virus infection in the etiology of fulminant type 1 diabetes, both environmental and genetic factors are largely unknown. Susceptibility to classic type 1A diabetes is determined by multiple genes within the HLA region and non-HLA genes, including INS-VNTR, CTLA4, and PTPN22 (2). Among them, CTLA4 is associated with autoimmunity, cancer, allergy, and infectious disease. In the CTLA4 region, a number of variants, such as +49G>A and CT60, have shown type 1 diabetes association (3). Although the association between class II HLA and fulminant type 1 diabetes has been reported (4), the contribution of the non-HLA genes to the susceptibility to fulminant type 1 diabetes has not been investigated. In this study, we examined the genetic contribution of the CTLA4 gene to fulminant type 1 diabetes compared with classic type 1A diabetes.
###end p 9
###begin title 10
RESEARCH DESIGN AND METHODS
###end title 10
###begin p 11
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
We examined 55 patients with fulminant type 1 diabetes (49% female, median age at onset 35.0 years), 91 patients with classic type 1A diabetes (57% female, median age at onset 17.0 years), and 369 healthy control subjects. Diagnostic criteria for fulminant type 1 diabetes are described elsewhere (1). The criteria for the recruitment of type 1A diabetic patients were presence of diabetic ketosis at onset, duration of hyperglycemic symptoms <3 months prior to initiation of insulin therapy, and positive for at least one of the anti-islet autoantibodies. This study was approved by the appropriate ethics committees, and informed consent was obtained from all subjects.
###end p 11
###begin p 12
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
Genotyping of two single nucleotide polymorphisms in the CTLA4 gene, +49G>A (rs231775) and CT60 (rs3087243), was performed as reported previously (5). Serum concentration of sCTLA4 was measured by enzyme-linked immunosorbent assay using human soluble CTLA4 (sCTLA4) kit (MedSystems Diagnostics, Vienna, Austria), according to the manufacturer's protocol. Sera from type 1 diabetic patients were obtained at disease onset and stored at -20degreesC until use.
###end p 12
###begin p 13
###xml 120 121 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 279 284 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 295 296 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The significance of differences in the distribution of genotypes between case and control subjects was determined by chi2 test or Fisher's exact probability test. Comparisons of the sCTLA4 levels were made by ANOVA with phenotypic group alone and ANOVA with phenotypic group and CTLA4 genotype. P < 0.05 was considered to be statistically significant.
###end p 13
###begin title 14
RESULTS
###end title 14
###begin p 15
###xml 104 111 104 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 421 422 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 474 477 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 576 579 576 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 605 608 605 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 740 741 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 822 825 822 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 906 913 906 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 486 493 <span type="species:ncbi:9606">patient</span>
###xml 699 707 <span type="species:ncbi:9606">patients</span>
###xml 779 787 <span type="species:ncbi:9606">patients</span>
The +49G>A variant was associated with classic type 1A diabetes but not with fulminant type 1 diabetes (Table 1). In contrast, the contribution of CT60 to disease is distinct from that of +49G>A. The frequency of the CT60AA genotype in fulminant type 1 diabetic patients was significantly higher than in control subjects (P = 0.021) and type 1A diabetic patients (P = 0.031). CT60GG was associated with type 1A diabetes (P = 0.008). Because of the strong association of HLA-DR4 in both patient groups (1), the effect of CTLA4 on type 1 diabetes susceptibility relative to HLA-DR4 was also examined. Among DR4-positive individuals, the frequency of the CT60AA genotype was significantly increased in patients with fulminant type 1 diabetes (P = 0.005). However, stratification of patients by the presence or absence of HLA-DR4 did not affect the association between the +49GG genotype and type 1A diabetes (Table 1).
###end p 15
###begin p 16
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 247 248 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 341 342 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 392 393 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 401 402 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 640 641 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 686 687 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
It has been reported that the CT60G allele might be associated with lower production of sCTLA4 mRNA (3). We therefore determined serum sCTLA4 levels. The mean sCTLA4 levels in fulminant type 1 diabetic patients (0.56 +/- 0.24 ng/ml [mean +/- SD], n = 36) was significantly lower than those in type 1A diabetic patients (0.94 +/- 0.87 ng/ml, n = 45) and control subjects (0.89 +/- 0.76 ng/ml, n = 23) (P = 0.043). A mixed-model ANOVA using phenotypic group (fulminant type 1 diabetes, type 1A diabetes, and control) and CT60 genotype (GG and GA+AA) as factorial fixed effects revealed no differences in sCTLA4 levels between CT60 genotypes (P = 0.76) or phenotype/genotype interactions (P = 0.40).
###end p 16
###begin title 17
CONCLUSIONS
###end title 17
###begin p 18
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 403 404 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 422 427 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 848 851 848 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
CTLA4, which delivers inhibitory signals to T-cell activation, is expressed on the surface of activated T-cells and regulatory T-cells, and the lack of CTLA4 results in uncontrolled T-cell-mediated lymphoproliferative disease (6). Furthermore, CTLA4 also has a significant biological role in attenuating T-cell responses in the context of an inflammatory environment, such as infection with a pathogen (7). We showed that CTLA4 is associated with an increased risk of fulminant type 1 diabetes and that its contribution is distinct from classic type 1A diabetes. As reported previously (5,8), a significant association between classic type 1A diabetes and +49GG and CT60GG genotype was also found in the present study. However, the CT60AA genotype contributes to the susceptibility to fulminant type 1 diabetes. Moreover, it is implicated that HLA-DR4 influences the association of fulminant type 1 diabetes with the CT60AA genotype.
###end p 18
###begin p 19
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
In this study, we also revealed that serum sCTLA4 level in fulminant type 1 diabetic patients were significantly lower than those in type 1A diabetic patients and control subjects. Although it remains unknown how sCTLA4 regulates T-cell activation, recombinant sCTLA4 inhibits T-cell proliferation in vitro. Furthermore, sCTLA4 is constitutively expressed in nonstimulated T-cells, and its expression is downregulated after T-cell activation (9). Therefore, the decreased levels of sCTLA4 might indicate a lower potential of T-cell inhibition in fulminant type 1 diabetes, which might be caused by functional defects leading to reduced production of sCTLA4 or ongoing activation of the immune system eventually leading to decreased levels of sCTLA4.
###end p 19
###begin p 20
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
In conclusion, the present study implicates that CTLA4 confers susceptibility to fulminant type 1 diabetes. Furthermore, the different contributions of CTLA4 to susceptibility to fulminant and classic type 1A diabetes indicate that the underlying immune process-primed beta-cell injury might be distinct between these subtypes of type 1 diabetes.
###end p 20
###begin p 21
This study was partly supported by a grant from the Ministry of Education, Culture, Science, Sports and Technology of Japan.
###end p 21
###begin p 22
We thank Shinobu Mitsui for excellent technical assistance.
###end p 22
###begin title 23
References
###end title 23
###begin p 24
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
CTLA4 polymorphisms in fulminant type 1 diabetic patients, type 1A diabetic patients, and healthy control subjects
###end p 24
###begin p 25
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 93 94 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 178 181 176 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
Data are n (%). The interaction between CTLA4 polymorphisms and HLA-DR4 was assessed by a chi2 test with a 2 x 2 contingency table (+49 GG vs. AG + AA or CT60 AA vs. AG + GG) in DR4-positive or -negative patients and the corresponding control subjects.
###end p 25

